Bio Spectrum - June 2018
Get Bio Spectrum along with 5,000+ other magazines & newspapers
Try FREE for 7 days
Latest and past issues of 5,000+ magazines & newspapers
Digital Access. Cancel Anytime.
Share with 4 family members.1 Year$99.99
Latest and past issues of 5,000+ magazines & newspapersDigital Access. Cancel Anytime.Share with 4 family members.Get Bio Spectrum
1 Year $10.99
Save 7%12 issues starting from August 2021 Digital Access. Cancel Anytime.Buy this issue $0.99
June 2018 issue Digital Access. - Magazine Details
- In this issue
Magazine Description
In this issue
GOVT’S HEALTHCARE & S&T POLICIES FORWARD LOOKING: INDUSTRY The Modi Ministry took charge in New Delhi on May 27 four years ago. In its election manifesto, Bharatiya Janata Party (BJP) government headed by Narendra Modi had clearly mentioned that it accords high priority to health sector, which is crucial for securing the economy. It also noted that the overarching goal of healthcare would be to provide, ‘Health Assurance to all Indians and to reduce the out of pocket spending on health care’, with the help of state governments. Now with completion of four years in office of Modi government, BioSpectrum spoke to the industry about the achievements of the government and what are the issues that still need the government’s attention.
Cancel Anytime [ No Commitments ]
Digital Only
“Our allergic rhinitis drug is technologically superior, masks bitterness and 52% cheaper”
Alok Malik, Group Vice President & Head, India Formulations, Glenmark Pharmaceuticals, Mumbai
Techade REDEFINING FUTURE OF life sciences industry
Digital transformation is the topmost priority for global corporations and in a highly connected world that will remain largely contactless for an extended period, there are shifts in business models, customer experience, operations, and employee experience. With technology adoption accelerating across sectors, 2021 is likely to put the spotlight on the emergence of growth verticals in the life sciences sector namely healthcare, pharma, medical devices, diagnostics etc. India is now standing at the cusp of a re-imagined decade of technology, commonly being referred to as ‘Techade’. While we anticipate a significantly better global economic growth this year as compared to 2020, we are also very much looking forward to the enhancement being brought to the Indian life sciences industry as it continues its transformation journey in this redefined techade.
Multifarious Cataract cures emerge
Being documented as India’s most significant cause of bilateral blindness that is for both eyes, cataract has become an economic and social burden that is increasing with the ageing population.
WHO Updates Guidelines For TB Detection
The World Health Organization (WHO) has issued an update to its consolidated guidelines on the detection of tuberculosis (TB) and drug-resistant TB.
Is The 5G Health Scare Unfounded?
The introduction of the 5G network has been mired in numerous controversies. Governments across the globe, activists and telecom operators are embroiled in a bitter fight, filing lawsuits and protesting in large numbers. Although most of the available research on electromagnetic fields (EMF) reveals that there are no harmful effects from mobile radiation, some studies do reveal that it has the potential to damage the very structure of the DNA. Cancer, impaired reproductive health and numerous other disorders, including psychiatric, have been attributed to 5G. Will the implementation of the 5G network have serious health implications, or are these fears unfounded? We try to weigh-in the opposing sides.
Is Antibody Cocktail Offering The Right Mix?
Although the clinical outcomes, as well as clinical trials, have been very promising for patients treated with the antibody cocktail so far, the Delta plus variant is considered to be resistant to the monoclonal antibody (mAb) cocktail treatment.
Stride Ventures leads Rs 25 Cr debt round in MediBuddy
Stride Ventures, one of India’s leading venture debt funds, has led a debt round of Rs 25 crore in Bengaluru-based startup MediBuddy that helps its users consult specialist doctors, order medicines and book lab tests from the comfort of their homes.
‘‘We see growing interest of healthcare testing labs, Pharmaceutical QC and R&D labs in implementing next-gen lab automation solutions''
US-based Abbott Informatics, formerly known as STARLIMS, is one of the companies with a long and established presence in the space of lab automation. Taking pride in offering the world class technological solutions, the company has recently announced the launch of STARLIMS Quality Manufacturing Solution QM12.2 which is built on the latest STARLIMS Technology V12 platform, along with STARLIMS SDMS (Scientific Data Management System) V12.2. To find out more about the company’s automated offerings in India, BioSpectrum spoke to Pradeep Nagisetty, Regional Sales Manager - India & Sub Continent, Abbott Informatics - STARLIMS, Hyderabad.
‘Juvenile Idiopathic Arthritis' remains a puzzle
LET'S TALK HEALTH & SCIENCE
India proposes BRICS Consortium to tackle NCDs as flagship programme
Experts deliberated on emerging issues in the various fields of Biotechnology and Biomedicine at the fourth BRICS Working Group meeting on the subject area.
